powered by Microsoft News Jump to navigation Skip to content Skip to footer Change language and content: Afrique francophone (français)Latin America (Spanish)Argentina (Spanish)Australia (English)België (Nederlands)Belgique (français)Brazil (português)Canada (English)Canada (français)Česká republika (čeština)Chile (Spanish)Colombia (Spanish)Danmark (Dansk)Deutschland (Deutsch)Spain Spanish)France (français)India (English)India (मराठी)India (हिंदी)India (বাংলা)India (తెలుగు)Indonesia (Bahasa Indonesia)International Edition (English)Ireland (English)Italy Italian)Magyarország (magyar)Malaysia (English)Mexico …
Read More »Tommy Tuberville: ‘Maybe’ to the Doug Jones debate and ‘no’ to the mandatory masks
A day after winning the Republican nomination for the United States Senate, Tommy Tuberville said he would probably accept a debate with Senator Doug Jones, but did not say it was a sure thing. “Maybe,” Tuberville told AL.com. “What we are seeing is as a team. I probably need to …
Read More »Former Naya Rivera’s ‘Glee’ co-star Heather Morris pays tribute to late actress
Naya Rivera received a moving tribute from her friend and former “Glee” co-star Heather Morris. Rivera was pronounced dead at age 33 on July 13 after disappearing on July 8 during an afternoon at Lake Piru in California with her 4-year-old son Josey. Forensic doctors confirmed that the cause of …
Read More »S&P 500 Increases With News About Coronavirus Vaccine: Travel And Entertainment Stocks Have A Great Day
More good news about a possible COVID-19 vaccine that looks promising. the S&P 500 (SNPINDEX: ^ SPX) collected 29 points, or just under 1%, on July 15, after publishing the results of a phase 1 study of Modern‘s (NASDAQ: MRNA) COVID-19 vaccine candidate. The results were promising, showing that all …
Read More »CytoDyn file application with Nasdaq for top list OTC markets: CYDY
VANCOUVER, Washington, July 15, 2020 (GLOBE NEWSWIRE) – CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), an advanced-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with potential for multiple therapeutic indications, announced today that it recently submitted a complete listing request package with The Nasdaq Stock Market to …
Read More »